Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis

Vogelstein, 1993, The multistep nature of cancer, Trends Genet, 9, 138, 10.1016/0168-9525(93)90209-Z Sarasin, 2003, An overview of the mechanisms of mutagenesis and carcinogenesis, Mutat Res, 544, 99, 10.1016/j.mrrev.2003.06.024 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Tan, 2001, Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis, J Clin Invest, 108, 1411, 10.1172/JCI14451 Looi, 2008, Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma, J Proteome Res, 7, 4004, 10.1021/pr800273h Zhang, 2011, Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma, J Proteome Res, 10, 2863, 10.1021/pr200141c Peng, 2013, Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis, J Proteome Res, 10.1021/pr3011342 Tan, 2008, Autoantibodies to tumor-associated antigens: reporters from the immune system, Immunol Rev, 222, 328, 10.1111/j.1600-065X.2008.00611.x Zhang, 2010, Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors, Expert Rev Mol Diagn, 10, 321, 10.1586/erm.10.12 Soussi, 2000, p53 antibodies in the sera of patients with various types of cancer. A review, Cancer Res, 60, 1777 Crawford, 1982, Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer, Int J Cancer, 30, 403, 10.1002/ijc.2910300404 Looi, 2006, Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies, Oncol Rep, 16, 1105 Yamamoto, 1999, Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients, Oncology, 56, 129, 10.1159/000011953 Disis, 1997, High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer, J Clin Oncol, 15, 3363, 10.1200/JCO.1997.15.11.3363 Junttila, 2007, CIP2A inhibits PP2A in human malignancies, Cell, 130, 51, 10.1016/j.cell.2007.04.044 Soo Hoo, 2002, Cloning and characterization of a novel 90kDa ‘companion’ auto-antigen of p62 overexpressed in cancer, Oncogene, 21, 5006, 10.1038/sj.onc.1205625 Liu, 2011, Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis, Autoimmun Rev, 10, 331, 10.1016/j.autrev.2010.12.002 Keene, 1999, Why is Hu where? Shuttling of early response gene messenger RNA subsets, Proc Natl Acad Sci U S A, 96, 5, 10.1073/pnas.96.1.5 Stockert, 1998, A survey of humoral immune response of cancer patients to a panel of human tumor antigens, J Exp Med, 187, 1349, 10.1084/jem.187.8.1349 Ambrosini, 1997, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma, Nat Med, 3, 917, 10.1038/nm0897-917 Daniels, 2005, Antinuclear autoantibodies in PCa: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis, Prostate, 62, 14, 10.1002/pros.20112 Winter, 1992, Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation, Cancer Res, 52, 4168 Lu, 2001, Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis, Am J Pathol, 159, 945, 10.1016/S0002-9440(10)61770-1 Anderson, 2005, The sentinel within: exploiting the immune system for cancer biomarkers, J Proteome Res, 4, 1123, 10.1021/pr0500814 Old, 1998, New paths in human cancer serology, J Exp Med, 187, 1163, 10.1084/jem.187.8.1163 Zhang, 2003, Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens, Cancer Epidemiol Biomarkers Prev, 12, 136 Imai, 1993, Novel nuclear antoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma, J Clin Invest, 92, 2419, 10.1172/JCI116848 Landberg, 1994, Characterization of a DNA-binding nuclear autoantigen mainly associated with S phase and G2 cells, Exp Cell Res, 212, 255, 10.1006/excr.1994.1141 Casiano, 1993, Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis, J Cell Sci, 106, 1045, 10.1242/jcs.106.4.1045 Zhang, 1999, A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma, J Exp Med, 189, 1101, 10.1084/jem.189.7.1101 Chen, 1997, A testicular antigen aberrantly expressed in human cancers detected by autologous antibodyscreening, Proc Natl Acad Sci U S A, 94, 1914, 10.1073/pnas.94.5.1914 Sahin, 1995, Human neoplasms elicit multiple specific immune responses in the autologous host, Proc Natl Acad Sci U S A, 92, 11810, 10.1073/pnas.92.25.11810 Chambers, 1985, Isolation and analysis of cDNA clones expressing human lupus La antigen, Proc Natl Acad Sci U S A, 82, 2115, 10.1073/pnas.82.7.2115 Le Naour, 2002, Identification of tumor-associated antigens using proteomics, Technol Cancer Res Treat, 1, 257, 10.1177/153303460200100406 Le Naour, 2002, A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis, Mol Cell Proteomics, 1, 197, 10.1074/mcp.M100029-MCP200 Ginestier, 2002, Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers, Am J Pathol, 161, 1223, 10.1016/S0002-9440(10)64399-4 Tyers, 2003, From genomics to proteomics, Nature, 422, 193, 10.1038/nature01510 Gygi, 2000, Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology, Proc Natl Acad Sci U S A, 97, 9390, 10.1073/pnas.160270797 Iwadate, 2008, Clinical proteomics in cancer research-promises and limitations of current two-dimensional gel electrophoresis, Curr Med Chem, 15, 2393, 10.2174/092986708785909102 Imai, 1993, Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma, Cancer, 71, 26, 10.1002/1097-0142(19930101)71:1<26::AID-CNCR2820710106>3.0.CO;2-N Imai, 1993, Autoantibodies in viral hepatitis related hepatocellular carcinoma, Intervirology, 35, 73, 10.1159/000150297 Zhang, 2001, De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma, Clin Exp Immunol, 125, 3, 10.1046/j.1365-2249.2001.01585.x Koziol, 2003, Recursive partitioning as an approach to selection of immune markers for tumor diagnosis, Clin Cancer Res, 9, 5120 Shi, 2005, Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens, Prostate, 63, 252, 10.1002/pros.20181 Zhang, 2007, Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma, J Hepatol, 46, 107, 10.1016/j.jhep.2006.08.010 Chen, 2010, Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma, Cancer Lett, 289, 32, 10.1016/j.canlet.2009.07.016